SEC filing record
Primary Source · SEC.gov

RheoTek Medical LLC

2023 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalSold increasedForm D/A · 2024-09-062 events: 1 sold increased, 1 investors increasedLast filing 2024-09-06

Raised

$1M

Investors

15

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

RheoTek Medical LLC is a Delaware limited liability company that first filed a Form D on September 12, 2023 and most recently amended it on September 6, 2024 in the Biotechnology industry group. The offering claims Rule 506(b). RheoTek Medical LLC reported $1,085,000 sold from 15 investors of a $4,000,000 total offering as of the Form D filed September 6, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 376 Bleecker St, Unit 2, New York, NY 10014.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001989178
Entity NameRheoTek Medical LLC
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeLimited Liability Company
Jurisdiction of OrganizationDelaware
Issuer Address376 Bleecker St, Unit 2, New York, NY 10014
Phone(203) 494-2369
Industry / Fund TypeBiotechnology
Securities Type—
First Sale DateAugust 31, 2023
Filing DateSeptember 6, 2024
Accession Number0001989178-24-000002
Total Offering Amount$4,000,000
Total Amount Sold$1,085,000
Amount Remaining$2,915,000
Total Investors15
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$0
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)NY
Amendment Count2 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

2

latest Sep 6, 2024

Critical / warning

0 / 0

0 watch · 2 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

lapsed

Latest event Sold increase · Sep 6, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 2 filing events with values and deltas, latest 2024-09-06, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2024-09-06: 1 related person added and 1 removed against the filing of 2023-09-12; 3 now listed. The names are in the Terminal feed.

Daniel Mazzaferro

Executive Officer, Director · New York, NY

Steven Duddy

Executive Officer, Director · New York, NY

Scott Bartlett

Executive Officer, Director · New York, NY

Questions About RheoTek Medical LLC

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is RheoTek Medical LLC?

RheoTek Medical LLC is a Delaware limited liability company that filed a Form D with the SEC on September 6, 2024 in the Biotechnology industry group. The filing claims Rule 506(b).

Is RheoTek Medical LLC legit?

AltStreet does not rate legitimacy; it reports the public record. RheoTek Medical LLC filed a Form D with the SEC on September 6, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $1,085,000 sold to 15 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is RheoTek Medical LLC registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that RheoTek Medical LLC claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has RheoTek Medical LLC raised?

RheoTek Medical LLC reported $1,085,000 sold from 15 investors of a $4,000,000 total offering as of the Form D filed September 6, 2024.

Who can invest in RheoTek Medical LLC?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in RheoTek Medical LLC?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling RheoTek Medical LLC and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind RheoTek Medical LLC?

The Form D lists 3 related persons: Daniel Mazzaferro, executive officer, director; Steven Duddy, executive officer, director; Scott Bartlett, executive officer, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is RheoTek Medical LLC located?

The issuer's address on its SEC filings is 376 Bleecker St, Unit 2, New York, NY 10014. Its phone number of record is 203-494-2369. It is organized under the laws of Delaware.

How long is the RheoTek Medical LLC offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

What is RheoTek Medical LLC's revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.